By Vince Paolizzi, Director of NanoCool Sales, Peli BioThermal
Although the need for liquid nitrogen is likely to remain steady in the coming years, the bottleneck created by its complex handling needs will only worsen as temperature-sensitive therapies become more popular. This translates to issues related to the cost of these drugs; mitigating them will require a holistic approach that targets affordability along every point of a therapy’s development and commercialization. Doing so has widespread implications for patients, in terms of both affordability and accessibility, as many of these drugs are only approved for reimbursement as a treatment of last resort.
Ultimately, the increasing need for ultra-cold storage, coupled with the challenges that accompany this trend, is driving innovation across the biotherapeutics space. By working to bolster capacity and advance simplified storage technologies for these drugs, biopharma companies, shipping companies, and container suppliers are pioneering a future that enables greater patient access to more affordable life-saving treatments.